Elite in Acute Lymphoblastic Leukemia (ALL)

Dr. Karen R. Rabin

Internal Medicine
Kaiser Foundation Health Plan Of The Mid Atlantic States, Inc
1701 Twin Springs Rd, 
Halethorpe, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Acute Lymphoblastic Leukemia (ALL)
Kaiser Foundation Health Plan Of The Mid Atlantic States, Inc
1701 Twin Springs Rd, 
Halethorpe, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Karen Rabin is a primary care provider, practicing in Internal Medicine in Halethorpe, Maryland. Dr. Rabin is rated as an Elite provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Down Syndrome, Leukemia, and L1 Syndrome.

Her clinical research consists of co-authoring 121 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 89 articles and participated in 4 clinical trials in the study of Acute Lymphoblastic Leukemia (ALL).

Specialties
Internal Medicine
Licenses
Internal Medicine in MD
Languages Spoken
English
Hebrew
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

KAISER FOUNDATION HEALTH PLAN OF THE MID ATLANTIC STATES, INC
1701 Twin Springs Rd, Halethorpe, MD 21227
Other Locations
KAISER FOUNDATION HEALTH PLAN OF THE MID ATLANTIC STATES, INC
1221 Mercantile Ln, Largo, MD 20774

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Other, Procedure
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2025
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Key Adverse Events After Childhood Cancer
Key Adverse Events After Childhood Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Other
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Drug, Other, Radiation
Study Drug: Adavosertib
Study Phase: Phase 1
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: September 26, 2023
Intervention Type: Drug
Study Drugs: Adavosertib, Irinotecan Hydrochloride
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Enrollment Status: Completed
Publish Date: March 26, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

121 Total Publications

Performance of Two-Phase Designs for the Time-to-Event Outcome and a Case Study Assessing the Relapse Risk Associated With B-ALL Subtypes.
Performance of Two-Phase Designs for the Time-to-Event Outcome and a Case Study Assessing the Relapse Risk Associated With B-ALL Subtypes.
Journal: JCO clinical cancer informatics
Published: May 02, 2025
Similar Doctors
Advanced in Acute Lymphoblastic Leukemia (ALL)
Dr. Vishal K. Gupta
Internal Medicine
Advanced in Acute Lymphoblastic Leukemia (ALL)
Dr. Vishal K. Gupta
Internal Medicine
1001 S George St, 
York, PA 
 (47.6 miles away)
717-741-8003
Languages Spoken:
English
See accepted insurances

Vishal Gupta is a primary care provider, practicing in Internal Medicine in York, Pennsylvania. Dr. Gupta is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Hypomelanotic Disorder, Vitiligo, Gallbladder Disease, Gallbladder Removal, and Endoscopy.

Experienced in Acute Lymphoblastic Leukemia (ALL)
Dr. Lisa K. Higginbotham
Internal Medicine
Experienced in Acute Lymphoblastic Leukemia (ALL)
Dr. Lisa K. Higginbotham
Internal Medicine

Wellspan Medical Group

601 E Main St, 
Waynesboro, PA 
 (59.0 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lisa Higginbotham is a primary care provider, practicing in Internal Medicine in Waynesboro, Pennsylvania. Dr. Higginbotham is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are High Cholesterol, Familial Hypertension, Hypertension, and Glucocorticoid-Remediable Aldosteronism.

Experienced in Acute Lymphoblastic Leukemia (ALL)
Dr. Christopher G. Kanakry
Internal Medicine
Experienced in Acute Lymphoblastic Leukemia (ALL)
Dr. Christopher G. Kanakry
Internal Medicine
Johns Hopkins Hospital, 600 N Wolfe Street, 
Baltimore, MD 
 (5.1 miles away)
410-955-5000
Languages Spoken:
English

Christopher Kanakry is a primary care provider, practicing in Internal Medicine in Baltimore, Maryland. Dr. Kanakry is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Primary Immunodeficiency (PID), Primary T Cell Immunodeficiency, and Bone Graft.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rabin's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile